Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01168791 · ClinicalTrials.gov registry record · Phase 3
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
A Phase 3 study, sponsored by Alaunos Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 447
- Enrollment target
NCT01168791 is a Phase 3 study that has completed, run by Alaunos Therapeutics. The registered enrollment target is 447 participants.
The verdict
NCT01168791, a Phase 3 study, has completed, sponsored by Alaunos Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 447 participants
- Enrollment target
Study Summary
This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma (STS).
Interventions
- DRUG doxorubicin in combination with palifosfamide-tris
- DRUG doxorubicin in combination with placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01168791
The ClinicalTrials.gov registry entry for NCT01168791 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 447 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which doxorubicin in combination with palifosfamide-tris is the first listed.
NCT01168791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01168791 about?
NCT01168791 is a clinical study titled "Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma". This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma ...
What is the current status of trial NCT01168791?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 447 participants. The study started on 2010-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01168791?
The interventions under investigation include: doxorubicin in combination with palifosfamide-tris (DRUG), doxorubicin in combination with placebo (DRUG).
Who is sponsoring clinical trial NCT01168791?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.